SCHEMBL1361437

SCHEMBL1361437

O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(Cl)cc3)n2)c1)c1ccccc1

nearest known ligand 0.91

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 13/20 0.91
ERBB2 P04626 13/20 0.91
KDR P35968 5/20 0.81
LCK P06239 3/20 0.81
IGF1R P08069 12/20 0.77
CSF1R P07333 3/20 0.76
RET P07949 3/20 0.76
FLT1 P17948 3/20 0.76
STK3 Q13188 3/20 0.76
MAP4K5 Q9Y4K4 3/20 0.76
MAP4K4 O95819 2/20 0.76
TAOK1 Q7L7X3 2/20 0.76
MAP4K2 Q12851 2/20 0.76
LRRK2 Q5S007 1/20 0.76
PTK2 Q05397 3/20 0.65
CDK19 Q9BWU1 2/20 0.65
FLT3 P36888 2/20 0.62
AURKA O14965 1/20 0.62
PRKD3 O94806 1/20 0.62
INSR P06213 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1361289 0.95 EGFR (1.00) EGFRERBB2KDRLCKIGF1R
SCHEMBL1364275 0.92 EGFR (0.91) EGFRERBB2KDRLCKIGF1R
SCHEMBL1363720 0.90 KDR (1.00) EGFRERBB2KDRLCKIGF1R
SCHEMBL1363144 0.89 EGFR (0.85) EGFRERBB2KDRLCKIGF1R
SCHEMBL1362277 0.89 EGFR (0.88) EGFRERBB2KDRLCKIGF1R
SCHEMBL1362161 0.89 EGFR (0.88) EGFRERBB2KDRLCKIGF1R
SCHEMBL1363158 0.89 EGFR (0.88) EGFRERBB2KDRLCKIGF1R
SCHEMBL1363706 0.89 EGFR (0.89) EGFRERBB2KDRLCKIGF1R
SCHEMBL1361389 0.88 IGF1R (0.82) EGFRERBB2KDRLCKIGF1R
SCHEMBL1363081 0.88 EGFR (1.00) EGFRERBB2KDRLCKIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US claimed
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US disclosed
EP-2222682-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2010-09-01 EP disclosed
US-20090253723-A1 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
WO-2009070516-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253723-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 EGFR 591/4885ERBB2 270/4885KDR 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.